Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Valent P, et al. Among authors: petzer al. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7. Crit Rev Oncol Hematol. 2012. PMID: 21903413 Review.
First annual report of the Austrian CML registry.
Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Schmidt S, et al. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. Wien Klin Wochenschr. 2010. PMID: 20936366
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. Petzer AL, et al. Haematologica. 2010 Jun;95(6):908-13. doi: 10.3324/haematol.2009.013979. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145273 Free PMC article. Clinical Trial.
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.
Petzer AL, Sperr WR, Buxhofer-Ausch V, Sliwa T, Schmidt S, Greil R, Wölfler A, Pichler P, Dormann C, Burgstaller S, Tinchon C, Lang A, Goebel F, Uthman S, Muenchmeier N, Valent P. Petzer AL, et al. Wien Klin Wochenschr. 2020 Aug;132(15-16):415-422. doi: 10.1007/s00508-020-01690-1. Epub 2020 Jun 12. Wien Klin Wochenschr. 2020. PMID: 32533444 Free PMC article.
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D. Petzer AL, et al. Haematologica. 2012 Oct;97(10):1562-9. doi: 10.3324/haematol.2011.060087. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511495 Free PMC article. Clinical Trial.
High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL, Hochenburger E, Haun M, Duba HCh, Grünewald K, Hoflehner E, Sill H, Linkesch W, Gastl G, Gunsilius E. Petzer AL, et al. J Hematother Stem Cell Res. 2002 Apr;11(2):293-300. doi: 10.1089/152581602753658475. J Hematother Stem Cell Res. 2002. PMID: 11983100 Clinical Trial.
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R. Egle A, et al. Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Ann Hematol. 2018. PMID: 29862437 Free PMC article. Clinical Trial.
127 results